Tags

Type your tag names separated by a space and hit enter

Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
J Antimicrob Chemother. 1997 May; 39 Suppl A:139-43.JA

Abstract

In recent years there has been a dramatic worldwide increase in the prevalence of multiple drug-resistant strains of common Gram-positive bacteria. This highlights the need for a new class of antibiotic with activity against these organisms. Quinupristin/dalfopristin, the first injectable streptogramin antibiotic, has a unique spectrum of activity, encompassing most Gram-positive cocci (including multi-drug-resistant strains), respiratory pathogens and anaerobes, Gram-positive, and a prolonged post-antibiotic effect. Quinupristin/ dalfopristin is active in vitro against multi-drug-resistant isolates of Staphylococcus aureus, coagulase-negative staphylococci, penicillin-resistant pneumococci and vancomycin-resistant Enterococcus faecium. Clinical case reports have shown that the combination is active against intra-abdominal, aortic graft, bacteraemia and hydrocephalus shunt infections caused by multi-drug-resistant enterococci, particularly E. faecium. In almost all of these clinical situations the enterococcal infection had displayed resistance to all other antimicrobial therapies. Preliminary clinical data have demonstrated the activity of quinupristin/ dalfopristin against S. aureus bacteraemia, and quinupristin/dalfopristin may also prove useful in the treatment of pneumococcal infections. Thus, possible future applications of the combination include the treatment of multi-drug-resistant strains of staphylococci, streptococci and enterococci. Quinupristin/dalfopristin may prove useful in the treatment of staphylococcal infections in children, invasive systemic pneumococcal infections, and nosocomial and community-acquired Gram-positive infections in patients unable to tolerate beta-lactam antimicrobial agents or glycopeptide antibiotics.

Authors+Show Affiliations

Chaim Sheba Medical Center, Tel Aviv University School of Medicine, Israel.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9511078

Citation

Rubinstein, E, and F Bompart. "Activity of Quinupristin/dalfopristin Against Gram-positive Bacteria: Clinical Applications and Therapeutic Potential." The Journal of Antimicrobial Chemotherapy, vol. 39 Suppl A, 1997, pp. 139-43.
Rubinstein E, Bompart F. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential. J Antimicrob Chemother. 1997;39 Suppl A:139-43.
Rubinstein, E., & Bompart, F. (1997). Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential. The Journal of Antimicrobial Chemotherapy, 39 Suppl A, 139-43.
Rubinstein E, Bompart F. Activity of Quinupristin/dalfopristin Against Gram-positive Bacteria: Clinical Applications and Therapeutic Potential. J Antimicrob Chemother. 1997;39 Suppl A:139-43. PubMed PMID: 9511078.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential. AU - Rubinstein,E, AU - Bompart,F, PY - 1997/5/1/pubmed PY - 1998/3/25/medline PY - 1997/5/1/entrez SP - 139 EP - 43 JF - The Journal of antimicrobial chemotherapy JO - J Antimicrob Chemother VL - 39 Suppl A N2 - In recent years there has been a dramatic worldwide increase in the prevalence of multiple drug-resistant strains of common Gram-positive bacteria. This highlights the need for a new class of antibiotic with activity against these organisms. Quinupristin/dalfopristin, the first injectable streptogramin antibiotic, has a unique spectrum of activity, encompassing most Gram-positive cocci (including multi-drug-resistant strains), respiratory pathogens and anaerobes, Gram-positive, and a prolonged post-antibiotic effect. Quinupristin/ dalfopristin is active in vitro against multi-drug-resistant isolates of Staphylococcus aureus, coagulase-negative staphylococci, penicillin-resistant pneumococci and vancomycin-resistant Enterococcus faecium. Clinical case reports have shown that the combination is active against intra-abdominal, aortic graft, bacteraemia and hydrocephalus shunt infections caused by multi-drug-resistant enterococci, particularly E. faecium. In almost all of these clinical situations the enterococcal infection had displayed resistance to all other antimicrobial therapies. Preliminary clinical data have demonstrated the activity of quinupristin/ dalfopristin against S. aureus bacteraemia, and quinupristin/dalfopristin may also prove useful in the treatment of pneumococcal infections. Thus, possible future applications of the combination include the treatment of multi-drug-resistant strains of staphylococci, streptococci and enterococci. Quinupristin/dalfopristin may prove useful in the treatment of staphylococcal infections in children, invasive systemic pneumococcal infections, and nosocomial and community-acquired Gram-positive infections in patients unable to tolerate beta-lactam antimicrobial agents or glycopeptide antibiotics. SN - 0305-7453 UR - https://www.unboundmedicine.com/medline/citation/9511078/Activity_of_quinupristin/dalfopristin_against_gram_positive_bacteria:_clinical_applications_and_therapeutic_potential_ L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/39.suppl_1.139 DB - PRIME DP - Unbound Medicine ER -